Endocrine-Related Cancer

References

1. ↵
   1. Barendsen GW

   1982 Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. International Journal of Radiation Oncology, Biology, Physics 8 1981–1997.
2. ↵
   1. Benua RS,
   2. Cicale NR,
   3. Sonenberg M &
   4. Rawson RW

   1962 The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 87 171–182.
3. ↵
   1. Bolch WE,
   2. Eckerman KF,
   3. Sgouros G &
   4. Thomas SR

   2009 MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry – standardization of nomenclature. Journal of Nuclear Medicine 50 477–484.
4. ↵
   1. Capoccetti F,
   2. Criscuoli B,
   3. Rossi G,
   4. Ferretti F,
   5. Manni C &
   6. Brianzoni E

   2009 The effectiveness of ¹²⁴I PET/CT in patients with differentiated thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging 53 536–545.
5. ↵
   1. Chiesa C,
   2. Castellani MR,
   3. Vellani C,
   4. Orunesu E,
   5. Negri A,
   6. Azzeroni R,
   7. Botta F,
   8. Maccauro M,
   9. Aliberti G,
   10. Seregni E
   11. et al.

   2009 Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging 53 546–561.
6. ↵
   1. Crawford DC,
   2. Flower MA,
   3. Pratt BE,
   4. Hill C,
   5. Zweit J,
   6. McCready VR &
   7. Harmer CL

   1997 Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. European Journal of Nuclear Medicine 24 1470–1478.
7. ↵
   1. Dale RG

   1996 Dose–rate effects in targeted radiotherapy. Physics in Medicine and Biology 41 1871–1884.
8. ↵
   1. De Klerk JM &
   2. Oyen WJ

   2009 The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases. Minerva Endocrinologica 34 57–69.
9. ↵
   1. Dorn R,
   2. Kopp J,
   3. Vogt H,
   4. Heidenreich P,
   5. Carroll RG &
   6. Gulec SA

   2003 Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. Journal of Nuclear Medicine 44 451–456.
10. ↵
    1. Eschmann SM,
    2. Reischl G,
    3. Bilger K,
    4. Kupferschlager J,
    5. Thelen MH,
    6. Dohmen BM,
    7. Besenfelder H &
    8. Bares R

    2002 Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. European Journal of Nuclear Medicine and Molecular Imaging 29 760–767.
11. ↵
    1. Flux GD,
    2. Haq M,
    3. Chittenden SJ,
    4. Buckley S,
    5. Hindorf C,
    6. Newbold K &
    7. Harmer CL

    2010 A dose–effect correlation for radioiodine ablation in differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 37 270–275.
12. ↵
    1. Freudenberg LS,
    2. Jentzen W,
    3. Gorges R,
    4. Petrich T,
    5. Marlowe RJ,
    6. Knust J &
    7. Bockisch A

    2007 ¹²⁴I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 46 121–128.
13. ↵
    1. Freudenberg LS,
    2. Fromke C,
    3. Petrich T,
    4. Marlowe RJ,
    5. Koska WW,
    6. Brandau W,
    7. Eising EG,
    8. Knust EJ,
    9. Bockisch A &
    10. Jentzen W

    2009 Thyroid remnant dose: ¹²⁴I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Experimental and Clinical Endocrinology and Diabetes[in press].
14. ↵
    1. Hänscheid H,
    2. Lassmann M,
    3. Luster M,
    4. Thomas SR,
    5. Pacini F,
    6. Ceccarelli C,
    7. Ladenson PW,
    8. Wahl RL,
    9. Schlumberger M,
    10. Ricard M
    11. et al.

    2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine 47 648–654.
15. ↵
    1. Hänscheid H,
    2. Lassmann M,
    3. Luster M,
    4. Kloos RT &
    5. Reiners C

    2009 Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocrine-Related Cancer 16 1283–1289.
16. ↵
    1. Haq MS,
    2. McCready RV &
    3. Harmer CL

    2004 Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy. Nuclear Medicine Communications 25 799–805.
17. ↵
    1. Hobbs RF,
    2. Wahl RL,
    3. Lodge MA,
    4. Javadi MS,
    5. Cho SY,
    6. Chien DT,
    7. Ewertz ME,
    8. Esaias CE,
    9. Ladenson PW &
    10. Sgouros G

    2009 ¹²⁴I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. Journal of Nuclear Medicine 50 1844–1847.
18. ↵
    1. Jentzen W,
    2. Schneider E,
    3. Freudenberg L,
    4. Eising EG,
    5. Gorges R,
    6. Muller SP,
    7. Brandau W &
    8. Bockisch A

    2006 Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer. Nuclear Medicine Communications 27 669–676.
19. ↵
    1. Jentzen W,
    2. Freudenberg L,
    3. Eising EG,
    4. Sonnenschein W,
    5. Knust J &
    6. Bockisch A

    2008 Optimized ¹²⁴I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. Journal of Nuclear Medicine 49 1017–1023.
20. ↵
    1. Jentzen W,
    2. Hobbs RF,
    3. Stahl A,
    4. Knust J,
    5. Sgouros G &
    6. Bockisch A

    2010 Pre-therapeutic ¹²⁴I PET(/CT) dosimetry confirms low average absorbed doses per administered ¹³¹I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 37 884–895.
21. ↵
    1. de Keizer B,
    2. Brans B,
    3. Hoekstra A,
    4. Zelissen PM,
    5. Koppeschaar HP,
    6. Lips CJ,
    7. van Rijk PP,
    8. Dierckx RA &
    9. de Klerk JM

    2003 Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. European Journal of Nuclear Medicine and Molecular Imaging 30 367–373.
22. ↵
    1. Kolbert KS,
    2. Pentlow KS,
    3. Pearson JR,
    4. Sheikh A,
    5. Finn RD,
    6. Humm JL &
    7. Larson SM

    2007 Prediction of absorbed dose to normal organs in thyroid cancer patients treated with ¹³¹I by use of ¹²⁴I PET and 3-dimensional internal dosimetry software. Journal of Nuclear Medicine 48 143–149.
23. ↵
    1. Kulkarni K,
    2. Van Nostrand D,
    3. Atkins F,
    4. Aiken M,
    5. Burman K &
    6. Wartofsky L

    2006 The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 16 1019–1023.
24. ↵
    1. Lassmann M,
    2. Luster M,
    3. Hänscheid H &
    4. Reiners C

    2004 Impact of ¹³¹I diagnostic activities on the biokinetics of thyroid remnants. Journal of Nuclear Medicine 45 619–625.
25. ↵
    1. Lassmann M,
    2. Hanscheid H,
    3. Chiesa C,
    4. Luster M,
    5. Bombardieri E &
    6. Reiners C

    2007 Blood dose calculation in radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 34 S199.
26. ↵
    1. Lassmann M,
    2. Hänscheid H,
    3. Chiesa C,
    4. Hindorf C,
    5. Flux G &
    6. Luster M

    2008 EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging 35 1405–1412.
27. ↵
    1. Lassmann M,
    2. Hänscheid H,
    3. Gassen D,
    4. Biko J,
    5. Meineke V,
    6. Reiners C &
    7. Scherthan H

    2010 In-vivo γ-H2AX and 53BP1 focus formation in blood cells after radioiodine therapy of differentiated thyroid cancer. Journal of Nuclear Medicine[in press].
28. ↵
    1. Lee JJ,
    2. Chung JK,
    3. Kim SE,
    4. Kang WJ,
    5. Park do J,
    6. Lee DS,
    7. Cho BY &
    8. Lee MC

    2008 Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Annals of Nuclear Medicine 22 727–734.
29. ↵
    1. Leeper RD

    1985 Thyroid cancer. Medical Clinics of North America 69 1079–1096.
30. ↵
    1. Li WB,
    2. Friedland W,
    3. Pomplun E,
    4. Jacob P,
    5. Paretzke HG,
    6. Lassmann M &
    7. Reiners C

    2001 Track structures and dose distributions from decays of I-131 and I-125 in and around water spheres simulating micrometastases of differentiated thyroid cancer. Radiation Research 156 419–429.
31. ↵
    1. Luster M,
    2. Sherman SI,
    3. Skarulis MC,
    4. Reynolds JR,
    5. Lassmann M,
    6. Hänscheid H &
    7. Reiners C

    2003 Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 30 1371–1377.
32. ↵
    1. Luster M,
    2. Lassmann M,
    3. Freudenberg LS &
    4. Reiners C

    2007 Thyroid cancer in childhood: management strategy, including dosimetry and long-term results. Hormones 6 269–278.
33. ↵
    1. Luster M,
    2. Clarke SE,
    3. Dietlein M,
    4. Lassmann M,
    5. Lind P,
    6. Oyen WJ,
    7. Tennvall J &
    8. Bombardieri E

    2008 Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 35 1941–1959.
34. ↵
    1. Maxon HR III. &
    2. Smith HS

    1990 Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinology and Metabolism Clinics of North America 19 685–718.
35. ↵
    1. Maxon HR,
    2. Thomas SR,
    3. Hertzberg VS,
    4. Kereiakes JG,
    5. Chen IW,
    6. Sperling MI &
    7. Saenger EL

    1983 Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. New England Journal of Medicine 309 937–941.
36. ↵
    1. Medvedec M

    2005 Thyroid stunning in vivo and in vitro. Nuclear Medicine Communications 26 731–735.
37. ↵
    1. Meier DA,
    2. Brill DR,
    3. Becker DV,
    4. Clarke SE,
    5. Silberstein EB,
    6. Royal HD &
    7. Balon HR

    2002 Procedure guideline for therapy of thyroid disease with (131)iodine. Journal of Nuclear Medicine 43 856–861.
38. ↵
    1. Menzel C,
    2. Grunwald F,
    3. Schomburg A,
    4. Palmedo H,
    5. Bender H,
    6. Spath G &
    7. Biersack HJ

    1996 “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma. Journal of Nuclear Medicine 37 1496–1503.
39. ↵
    1. O'Donoghue JA

    1999 Implications of nonuniform tumor doses for radioimmunotherapy. Journal of Nuclear Medicine 40 1337–1341.
40. ↵
    1. Pacini F,
    2. Ladenson PW,
    3. Schlumberger M,
    4. Driedger A,
    5. Luster M,
    6. Kloos RT,
    7. Sherman S,
    8. Haugen B,
    9. Corone C,
    10. Molinaro E
    11. et al.

    2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Journal of Clinical Endocrinology and Metabolism 91 926–932.
41. ↵
    1. Pentlow KS,
    2. Graham MC,
    3. Lambrecht RM,
    4. Daghighian F,
    5. Bacharach SL,
    6. Bendriem B,
    7. Finn RD,
    8. Jordan K,
    9. Kalaigian H,
    10. Karp JS
    11. et al.

    1996 Quantitative imaging of iodine-124 with PET. Journal of Nuclear Medicine 37 1557–1562.
42. ↵
    1. Prideaux AR,
    2. Song H,
    3. Hobbs RF,
    4. He B,
    5. Frey EC,
    6. Ladenson PW,
    7. Wahl RL &
    8. Sgouros G

    2007 Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. Journal of Nuclear Medicine 48 1008–1016.
43. ↵
    1. Remy H,
    2. Borget I,
    3. Leboulleux S,
    4. Guilabert N,
    5. Lavielle F,
    6. Garsi J,
    7. Bournaud C,
    8. Gupta S,
    9. Schlumberger M &
    10. Ricard M

    2008 ¹³¹I effective half-life and dosimetry in thyroid cancer patients. Journal of Nuclear Medicine 49 1445–1450.
44. ↵
    1. Salvatori M &
    2. Luster M

    2010 Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 37 821–828.
45. ↵
    1. Samuel AM,
    2. Rajashekharrao B &
    3. Shah DH

    1998 Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. Journal of Nuclear Medicine 39 1531–1536.
46. ↵
    Schlumberger M & Pacini F 2003 Thyroid Tumors. Paris: Editions Nucléon.
47. ↵
    1. Sgouros G,
    2. Kolbert KS,
    3. Sheikh A,
    4. Pentlow KS,
    5. Mun EF,
    6. Barth A,
    7. Robbins RJ &
    8. Larson SM

    2004 Patient-specific dosimetry for ¹³¹I thyroid cancer therapy using ¹²⁴I PET and 3-dimensional-internal dosimetry (3D-ID) software. Journal of Nuclear Medicine 45 1366–1372.
48. ↵
    1. Sgouros G,
    2. Song H,
    3. Ladenson PW &
    4. Wahl RL

    2006 Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose–rate method and dosimetric implications of the 80-mCi rule. Journal of Nuclear Medicine 47 1977–1984.
49. ↵
    1. Siegel JA,
    2. Thomas SR,
    3. Stubbs JB,
    4. Stabin MG,
    5. Hays MT,
    6. Koral KF,
    7. Robertson JS,
    8. Howell RW,
    9. Wessels BW,
    10. Fisher DR
    11. et al.

    1999 MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. Journal of Nuclear Medicine 40 37S–61S.
50. ↵
    1. Song H,
    2. He B,
    3. Prideaux A,
    4. Du Y,
    5. Frey E,
    6. Kasecamp W,
    7. Ladenson PW,
    8. Wahl RL &
    9. Sgouros G

    2006 Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. Journal of Nuclear Medicine 47 1985–1994.
51. ↵
    1. Stabin MG,
    2. Sparks RB &
    3. Crowe E

    2005 OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. Journal of Nuclear Medicine 46 1023–1027.
52. ↵
    1. Thomas SR,
    2. Samaratunga RC,
    3. Sperling M &
    4. Maxon HR III.

    1993 Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nuclear Medicine and Biology 20 157–162.
53. ↵
    1. Tuttle RM,
    2. Leboeuf R,
    3. Robbins RJ,
    4. Qualey R,
    5. Pentlow K,
    6. Larson SM &
    7. Chan CY

    2006 Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. Journal of Nuclear Medicine 47 1587–1591.
54. ↵
    1. Van Nostrand D,
    2. Atkins F,
    3. Yeganeh F,
    4. Acio E,
    5. Bursaw R &
    6. Wartofsky L

    2002 Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 12 121–134.
55. ↵
    1. Verburg FA,
    2. Hanscheid H,
    3. Biko J,
    4. Hategan MC,
    5. Lassmann M,
    6. Kreissl MC,
    7. Reiners C &
    8. Luster M

    2010 Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. European Journal of Nuclear Medicine and Molecular Imaging 37 896–903.